26th Annual Symposium of the International Cannabinoid Research Society. Bukovina, Poland. June 26-July 1, 2016.

Research on cannabis and sleep is emerging with promising results. This book offers current and comprehensive knowledge on cannabinoid research results in connection with sleep. The volume covers aspects of the hemp plant Cannabis sativa, the pharmacology of cannabinoids, neurobiology and pharmacology of sleep and wakefulness, and the benefits and side effects of cannabis on the central nervous system. It further discusses the putative therapeutical properties of cannabinoids and endocannabinoids and their potential for the treatment of sleep disorders such as insomnia, obstructive sleep apnea, REM sleep behavior disorder, and restless legs syndrome. The book is written by medical and scientific experts in this field and intended for researchers from a range of disciplines such as biomedicine, biology, neurosciences, clinical medicine, neurology, and pharmacology.

Cannabis sativa has a long history; however, it has not been fully exploited for its beneficial uses. This plant can solve many present challenges, including challenges found in the pharmaceutical and cosmetic industries. Bioprospecting of this very important plant can generate economic upliftment of weaker sections of society and states if properly used under rules and regulations. Cannabis sativa Cultivation, Production, and Applications in Pharmaceuticals and Cosmetics discusses in detail the current research conducted in the area of Cannabis sativa in order to make it more useful and sustainable for the future. It further focuses on the exploration of Cannabis sativa phytoconstituents in various fields, especially in the pharmaceutical and cosmetic industries. Covering topics such as bioactive properties, molecular modeling, and soil pollutants, this premier reference source is an excellent resource for pharmacologists, pharmacists, health professionals, food scientists, agricultural scientists, botanists, chemists, students and educators of higher education, librarians, researchers, and academicians.

The book presents the current state of the art on phytocannnabinoid chemistry and pharmacology and will be of much use to those wishing to understand the current landscape of the exciting and intriguing phytocannabinoid science. The focus is on natural product cannabinoids which have been demonstrated to act at specific receptor targets in the CNS.

The second edition of this critically acclaimed and award-winning text provides a comprehensive overview of the psychiatry and neuroscience of Cannabis sativa (marijuana). It outlines the very latest developments in our understanding of the human cannabinoid system, and links this knowledge to clinical and epidemiological facts about the impact of cannabis on mental health. Clinically focused chapters review not only the direct psychomimetic properties of cannabis, but also the impact consumption has on the courses of evolving or established mental illnesses such as schizophrenia. Effects of cannabis on mood are reviewed, as are its effects on cognition. This new edition has been extensively updated and expanded with ten new chapters to incorporate major new research findings. This book will be of interest to all members of the mental health team, as well as to neuroscientists, epidemiologists, public health specialists and those involved in drug and alcohol research.

Two award-winning journalists offer a “cogent, well-sourced and ambitious analysis of the slow decline of cannabis prohibition in the United States” (Kirkus Reviews). In November 2012, voters in Colorado and Washington passed landmark measures to legalize the production and sale of cannabis for social use—a first in the United States and the world. Once vilified as a “gateway drug,” cannabis is now legal for medical use in eighteen states and Washington, DC. Yet the federal government refuses to acknowledge these broader societal shifts. 49.5 percent of all drug-related arrests involve the sale, manufacture, or possession of cannabis. In the first book to explore the new landscape of cannabis in the United States, investigative journalists Alyson Martin and Nushin Rashidian demonstrate how recent cultural and legal developments tie into cannabis’s complex history and thorny politics. Reporting from nearly every state with a medical cannabis law, Martin and Rashidian interview patients, growers, doctors, entrepreneurs, politicians, activists, and regulators. A New Leaf moves from the federal cannabis farm at the University of Mississippi to the headquarters of the ACLU to Oregon’s World Famous Cannabis Café. The result is a lucid account of how cannabis legalization is changing the lives of millions of Americans and easing the burden of the “war on drugs” both domestically and internationally.

This book highlights current Cannabis research: its botany, authentication, biotechnology, in vitro propagation, chemistry, cannabinoids biosynthesis, metabolomics, genomics, biomass production, quality control, and pharmacology. Cannabis sativa L. (Family: Cannabaceae) is one of the oldest sources of fiber, food and medicine. This plant has been of interest to researchers, general public and media not only due to its medicinal properties but also the controversy surrounding its illicit use. Cannabis has a long history of medicinal use in the Middle East and Asia, being first introduced as a medicine in Western Europe in the early 19th century. Due to its numerous natural constituents, Cannabis is considered a chemically complex species. It contains a unique class of terpeno-phenolic compounds (cannabinoids or phytocannabinoids), which have been extensively studied since the discovery of the chemical structure of tetrah ydrocannabinol (Δ9-THC), commonly known as THC, the main constituent responsible for the plant’s psychoactive effects. An additionally important cannabinoid of current interest is Cannabidiol (CBD). There has been a significant interest in CBD and CBD oil (extract of CBD rich Cannabis) over the last few years because of its reported activity as an antiepileptic agent, particularly its potential use in the treatment of intractable epilepsy in children.